Lipid Lowering with Statins and Ezetimibe: The Role in 2017 - Álvaro Sosa Liprandi

↳ This is a section part of Moment: ISCP 2017 - Prevention and Treatment of Atherosclerosis

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Preview

Summary

Lipid Lowering with Statins and Ezetimibe: The Role in 2017 - Presented by Álvaro Sosa Liprandi at ISCP 2017.

Add this Moment to your Passport

Learn from this moment and keep it forever.
Add To Passport
$19.99
This moment is included in Simple Premium - Get started for free.
FREE with Simple Premium
Start your 30-day free trial
Simple Premium offers unlimited access to all premium moments. $30.00 per month. Cancel anytime.

Target Audience

  • Cardiologists, interventional Cardiologists
  • Interventional Fellows
  • Interventional Radiologists
  • Vascular Surgeons
  • Emergency Physicians

Learning Objectives

Other Components in this Moment

Overview
Lipid Lowering with Statins and Ezetimibe: The Role in 2017 - Álvaro Sosa Liprandi
Clinical Data with PCSK9 inhibitors - Alberto Lorenzatti
The Paradox of Smoking and Obesity During the Prevention of Atherosclerosis - Koji Hasegawa
Modulating Cardiovascular Risk with Antidiabetic therapy: The Big Surprise and Lessons for the Future - José Ramón González Juanatey
Refractory Hypertension: What is Essential to Know in 2017 - Thomas Kahan
Myocardial infarction and Non-Obstructive Coronary Arteries - Stefan Agewall
Discussion of ISCP 2017 - Prevention and Treatment of atherosclerosis
Loading Simple Education